hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 21:06:10 - browse：919

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout Newsletter: Ironwood, Pfizer, FogPharma updates

WSS

Why getting cancer drugs just got harder for rural patients

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

The new HIV moral panic

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

knowledge

hotspot

focus

The cancer drug shortage isn’t new — and neither are the solutions

Blood tests recalled over risk of missed heart attack diagnosis

DIEP, the 'gold standard' of breast reconstruction, is under threat

How to address the problem of discarded donor organs

In Memoriam: Notable people who died in 2023

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Trump demands the U.S. pay no more for drugs than other countries … again

Who gets to use the title 'doctor'?

Moonlake's readout produced a cash windfall. Risks remain

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

hotspot

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

How to address the problem of discarded donor organs

Clinical trials giant ICON acquires HumanFirst

Who gets to use the title 'doctor'?

explore

focus

focus

knowledge